ACE-536 granted rare disease designation for the treatment of beta-thalassemia and for the treatment of myelodysplastic syndromes (MDS)

WATERTOWN, Mass.--(BUSINESS WIRE)-- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today announced the pricing of its initial public offering of 10,714,286 shares of common stock at a price to the public of $7.00 per share, less underwriting discounts and commissions. Tetraphase's common stock is expected to begin trading on the NASDAQ Global Market under the symbol "TTPH" on March 20, 2013.

Tetraphase has granted the underwriters a 30-day option to purchase up to 1,607,143 additional shares of common stock at the same price to cover over allotments, if any.

Development License and Option Agreement Represents Blueprint for Innovation between Pharma and Biotech

SAN DIEGO, March 13, 2013 /PRNewswire/ – Receptos Inc. announced today that it has entered a Development License and Option Agreement to in-license a humanized anti-interleukin-13 (IL-13) antibody asset from AbbVie (ABBV).

Fourth Quarter and Full Year BGM Galectin-3 Test Sales Grow Significantly

• Q4 Revenues nearly triple from Q4 2011
• Product margins increase 10% from Q4 2011
• January 2013 $12.8 million public offering supplements Q4 2012 cash of $13.2 million
• bioMérieux obtains CE mark for VIDAS Galectin-3 test

WALTHAM, Mass.--(BUSINESS WIRE)--Avedro today announced that in preparation for its US clinical trial, a select group of US refractive surgeons have just completed Lasik Xtra procedure training under Gustavo Tamayo, MD, at the Bogota Laser Center in Bogota, Colombia.

Novel biologic has potential to treat rare blood disorder with substantial unmet medical need

SAN DIEGO, March 7, 2013 /PRNewswire/ -- Receptos, a biopharmaceutical company focused on developing therapeutic candidates directed to G-protein-coupled receptor (GPCR) targets, announced today that it has successfully determined a novel protein crystal structure of an undisclosed proprietary GPCR drug discovery target for Ono Pharmaceuticals.

WALTHAM, Mass., March 6, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc.

WALTHAM, Mass., Mar 05, 2013 (BUSINESS WIRE) -- Avedro, Inc. announced today the completion of a $43 million Series D financing led by Abingworth along with a significant investment by Third Point. Avedro's other investors include Prism Venture Works, De Novo Ventures, Flagship Ventures, Aperture Ventures, SCP Vitalife Partners, Borealis Ventures and Echelon Ventures.

As part of the transaction, David Mayer from Abingworth and Jason Hong, PhD from Third Point will be joining the Board of Directors.

A third of the waste that’s dumped into landfills is packaging such as boxes, bags, and food wrappers. David Edwards has a solution: Just eat it.

Last year, Edwards, 51, a bioengineer at Harvard, launched WikiCell, which makes edible packaging for everything from yogurt to coffee and even alcoholic drinks. “We can basically surround any food or beverage with a skin like a grape skin that’s fully edible, and then consume it,” he says. Picture a martini wrapped in an olive that you can stick in your pocket and rinse off when you’re ready for a toast.